Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours
- 17 November 2012
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 139 (3) , 447-455
Abstract
L19-TNF is an armed antibody that selectively targets human TNF to extra domain B-fibronectin on tumour blood vessels. We performed a phase I/II first-in-man trial with L19-TNF monotherapy in metastatic solid cancer patients to study safety and signs of clinical activity.Keywords
This publication has 36 references indexed in Scilit:
- Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumoursEuropean Journal of Cancer, 2010
- Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursBritish Journal of Cancer, 2009
- Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic OriginClinical Cancer Research, 2006
- Tumour vascular targetingNature Reviews Cancer, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastasesCancer, 1992
- Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancyEuropean Journal of Cancer and Clinical Oncology, 1991
- Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascitesEuropean Journal of Cancer and Clinical Oncology, 1991
- Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins.Journal of Experimental Medicine, 1989
- Systemische versus lokale Therapie mit rekombinantem Tumor-Nekrose-Faktor-alpha (r-TNF-alpha) bei Patienten mit fortgeschrittenen TumorenOncology Research and Treatment, 1989